Chris Boshoff, MD, PhD
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of dacomitinib (Vizimpro) for the frontline treatment of adult patients with metastatic non–small cell lung cancer (NSCLC) with EGFR
-activating mutations, according to Pfizer, the manufacturer of the pan-human EGFR TKI.
The European Commission will now review the CHMP recommendation and make a final decision on whether to approve dacomitinib for use in the European Union.
... to read the full story